Quick Answer
Spero Therapeutics, Inc. reported Operating Income of $6.31 million for fiscal year 2025.
Spero Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $6.31M | +108.6% |
| 2024 | -$73.36M | -441.5% |
| 2023 | $21.48M | +150.9% |
| 2022 | -$42.20M | +52.0% |
| 2021 | -$87.97M | -11.2% |
| 2020 | -$79.11M | -25.1% |
| 2019 | -$63.22M | -47.7% |
| 2018 | -$42.81M | -2.6% |
| 2017 | -$41.73M | -25.6% |
| 2016 | -$33.22M | -149.3% |
| 2015 | -$13.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.92M | +57.4% | -223.9% |
| June 30, 2025 | -$2.44M | +87.2% | +83.4% |
| March 31, 2025 | -$14.73M | -5.4% | +20.8% |
| September 30, 2024 | -$18.59M | -861.4% | +2.5% |
| June 30, 2024 | -$19.06M | -47.9% | -36.3% |
| March 31, 2024 | -$13.98M | +1.7% | -623.0% |
| September 30, 2023 | -$1.93M | +83.7% | +85.0% |
| June 30, 2023 | -$12.89M | +50.6% | +9.4% |
- Spero Therapeutics, Inc. showed an increase of +108.6% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Spero Therapeutics, Inc.’s operating income has grown by 147.4% (from -$13.33 million to $6.31 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: